ATHE

SEC filing ATHE Presents Phase 2 ATH434 Data, Plans Phase 3 in Multiple System Atrophy, Reports Statistically Significant Slowing of Disease Progression

14d ago

SEC filing ATHE Reports $0 Revenue, $0 EPS, Upcoming General Meeting May 29 2026 Online at investor.automic.com.au, Vote Proxy via Automic, Julian Babarczy & Ann Cunningham Director Elections, Capital Consolidation 1:50 Ratio

34d ago

SEC filing ATHE Reports April 2026 6-K Filing, Melbourne HQ, Australia Address, No Items Disclosed

36d ago

SEC filing ATHE Reports Positive FDA Feedback on ATH434 Phase 3 CMC Alignment, End-of-Phase 2 Meeting Targets Mid-2026

36d ago

SEC filing ATHE Reports $1.2B Revenue, $0.05 EPS, Announces $500M Capital Raise

43d ago

SEC filing ATHE Reports $1.2B Revenue, $0.05 EPS, Announces $500M Capital Raise

43d ago

SEC filing ATHE Proposes 150M Options at $0.02 Exercise, $0.0000001 Consideration, 2026 Issue

75d ago

SEC filing ATHE Announces CEO Dr. Stamler to Speak at Bell Potter Healthcare Horizons Summit, Fireside Chat on Optimising Late-stage Clinical Trials, 1-on-1 Investor Meetings, Phase 3 MSA Trial Prep, ATH434 Positive Data, Patent-protected Neurodegenerative Platform

85d ago

Scanner Unusual buy pressure (4.4x avg, 62% up-volume, +6.5% / +0.22 intraday, above VWAP)

89d ago

SEC filing 8-K Filing

123d ago

News Seagate Stock Sets Record After Earnings. Why Western Digital and Sandisk Are Also Rallying.

124d ago

News These Stocks Are Today’s Movers: Seagate, Amphenol, Texas Instruments, Nvidia, Tesla, AT&T, Nextpower, and More

125d ago